Table 1 Characteristics of patients with advanced NSCLC
Age in years (mean ± SD) | 59.6 ± 14 |
|---|---|
Gender (males, n, %) | 60 (63.8%) |
Tobacco use | 30 (32%) |
Tumor characteristics | |
 T stage | |
  a. T2 | 12 (12.7%) |
  b. T3 | 48 (51.1%) |
  c. T4 | 34 (36.2%) |
 N stage | |
  a. N0 | 2 (2.1%) |
  b. N1 | 8 (8.5%) |
  c. N2 | 40 (42.5%) |
  d. N3 | 44 (46.8%) |
 Sites of metastasis | |
  1. Pleural | 41 (43.6%) |
  2. Brain | 11 (11.7%) |
  3. Skeletal | 14 (14.9%) |
  4. Pleural + brain | 5 (5.3%) |
  5. Pleural + skeletal | 18 (19.1%) |
  6. Brain + skeletal | 3 (3.2%) |
  7. Pleural + brain + skeletal | 2 (2.1%) |
 Stage | |
  1. IVa | 58 (61.7%) |
  2. IVb | 36 (38.3%) |
 ECOG PS | |
  a. 0 | 9 (9.6%) |
  b. 1 | 19 (20.2%) |
  c. 2 | 31 (33%) |
  d. 3 | 25 (26.6%) |
  e. 4 | 10 (10.6%) |
 Molecular mutation status | |
  1. EGFR | Wild- 66 (70.2%) |
Mutant- 28 (29.8%; exon 19–15; exon 21–8, exon 18–3, exon 20–2) | |
  2. ALK | 4 (4.2%) |
  3. ROS1 | 1 (1.1%) |